SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards as the community discusses concerns around declining traffic, margin pressures, and lowered sales outlook, potentially driven by consumer spending habits and pricing. Some traders believe the stock is oversold, presenting a buying opportunity, while others express concerns about the company's current leadership and competitive landscape. Community members are also debating if a change in strategy is needed to better appeal to a broader customer base.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to renewed optimism fueled by raised FY25 EBITDA guidance and a potential short squeeze, with the community actively discussing target prices and the possibility of further upside. A top-line Q3 beat and recent earnings surprise are adding to the positive sentiment. Some traders are closely monitoring the stock's short interest and anticipating a significant price movement.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Strive, following its merger with Asset Entities in mid-September, announced plans to become a Bitcoin holding company.</li><li>Bitcoin topped the $116K earlier in the Asian session, before giving back some of the gains.</li><li>The optimism toward cryptocurrencies stemmed from a raft of catalysts, including the brightening prospects of a U.S.-China deal.</li></ul>Strive Asset Management, LLC (ASST) stock climbed sharply in Monday’s early premarket session, signaling that it may rise for a third consecutive session.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ASST">Strive stock</a> remained ‘extremely bullish’ as of early Monday, and the message volume jumped to ‘extremely high’ levels.<h2 class="st-heading-2">Strive’s Bitcoin-Inspired Rally?</h2>Nasdaq-listed Asset Entities, a marketing company, closed its merger with asset management company Strive in mid-September, retaining the Strive name and ‘ASST’ ticker. The company, co-founded by Vivek Ramaswami, announced plans to become a Bitcoin (BTC) holding and marketing company.ASST’s premarket gains on Monday could be traced to strong gains in Bitcoin (BTC), which topped the $116K earlier in the Asian session,&nbsp;before giving back some of the gains. The optimism toward crypto stemmed from a raft of catalysts, including the brightening prospects of a U.S.-China deal following productive high-level talks between the two countries in Malaysia over the weekend.Hopes of a rate cut from the Federal Reserve’s rate-setting committee, when it meets for a two-day meeting that kicks off on Tuesday, also lent support to cryptocurrencies.<h2 class="st-heading-2">What Retail’s Feeling About Strive Stock</h2>Retail’s interest in Strive’s stock has been on the rise, with the one-year follower count rising 675% and the message volume over the past seven days leading up to late Sunday was up over 900%.A bullish watcher lauded the company for the bold move to merge and become the first public Bitcoin treasury company, backed by a massive $750 million funding plan. “Big vision, big potential!” they said.<stembedurl>https://stocktwits.com/StockGuru95/message/633790891</stembedurl>Another user expected algorithmic buying on Monday, just like last Friday, when it ripped before remaining stuck for a long time.<stembedurl>https://stocktwits.com/Ammylovlov/message/633790840</stembedurl>Since its mid-September listing, the stock has lost about 82%. In premarket, the stock climbed over 26% on top of Friday’s 27%+ rally.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-avidity-biosciences-stock-is-jumping-over-43-in-premarket-today/cLG0dICR3Ma">Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today</a>

Why Strive Stock Is Ripping Higher In Premarket Today

Strive Asset Management, LLC (ASST) stock climbed sharply in Monday’s early premarket session, signaling that it may rise for a third consecutive session.

Why Strive (ASST) Stock Is Ripping Higher In Premarket Today

Equity

<ul class="summary-bullets"><li>Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.</li><li>The deal is expected to close in the first half of 2026.</li><li>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago.</li></ul>Avidity Biosciences, Inc. (RNA) shares&nbsp;soared over 43% in Monday’s early premarket session after the mid-cap biopharma focusing on developing RNA therapeutics called antibody oligonucleotide conjugates (AOC), announced a deal to be bought by Swiss pharma giant Novartis (NVS).<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences</a> stock has gained more than 60% this year.<h2 class="st-heading-2">The Novartis Deal Terms</h2>In a statement released on Sunday, Novartis said it would acquire San Diego-based Avidity Biosciences following the separation of the latter’s early-stage precision cardiology programs. The deal, approved by the boards of both companies, is valued at $72 per share in cash. This represented a 46% premium over RNA stock’s closing price of $49.15 on Friday.The total transaction value is $12 billion on a fully diluted basis. Avidity Biosciences currently boasts a market capitalization of $7.17 billion.Vas Narasimhan, CEO of Novartis, said, “Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”Before the merger's closing, Avidity will transfer its early-stage precision cardiology programs and collaborations to SpinCo, a wholly owned subsidiary of Avidity. Holders of Avidity common stock will receive a distribution of one share of SpinCo for every ten shares of Avidity they hold and/or a pro rata cash distribution of the proceeds received by Avidity before the closing if certain SpinCo assets are, or SpinCo itself is, sold to a third party.The deal is expected to close in the first half of 2026, subject to the completion of a spin-off or the sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.Novartis said the proposed acquisition raises the expected 2024-2029 sales growth from 5% to 6% on a compounded annual growth rate (CAGR) basis, representing a significant opportunity to deliver substantial shareholder returns over time.<h2 class="st-heading-2">What Retail’s Saying About The Buyout Deal</h2>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago. The message volume on the stream also improved to ‘extremely high.’&nbsp; Retail chatter spiked 6,100% over the 24 hours leading up to late Sunday.<figure class="image"><img style="aspect-ratio:620/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_27_at_6_02_00_AM_png_9d47ea362a.webp" alt="Screenshot 2025-10-27 at 6.02.00 AM.png" width="620" height="56"><figcaption>RNA sentiment and message volume as of 6 a.m. ET, Oct. 27 | source: Stocktwits</figcaption></figure>A bullish user noted that RNA traded at $5 two years ago and congratulated the believers.<stembedurl>https://stocktwits.com/Cutlass/message/633766787</stembedurl>Another user said they would cash out on Monday.<stembedurl>https://stocktwits.com/ure300/message/633760283</stembedurl>Earlier this month, Avidity Biosciences said it has completed a positive pre-Biologic License Application (BLA) meeting with the FDA regarding its delpacibart zotadirsen, an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy (DMD) who have gene mutations amenable to exon 44 skipping.&nbsp;The timing for the BLA submission was pushed back to the first quarter of 2026 from the previous guidance of year-end 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-rises-premarket-today-as-stock-closes-in-on-200-psychological-threshold/cLG0TBNR3Md">Palantir Rises Premarket Today As Stock Closes In On $200 Psychological Threshold: What’s Driving The Gains?</a>

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Why Avidity Biosciences Stock Is Jumping Over 40% In Premarket Today

&nbsp;<ul class="summary-bullets"><li>In an amended&nbsp;regulatory filing, AiRWA confirmed a stake built by director Michael Anthony Belfiore.</li><li>According to the filing, he now holds a 22.1% stake in AiRWA.</li><li>Retail expects “FOMO” fear will kick in once the stock reaches $0.50.</li></ul>Nano-cap AiRWA, Inc.’s (YYAI) stock fell for two consecutive sessions this week, but rebounded by nearly 32% in Tuesday’s after-hours session, accompanied by substantial volume,&nbsp;following a filing by the company confirming an insider’s stake build.<a href="https://stocktwits.com/symbol/YYAI">AiRWA stock</a>, which has traded in a 52-week range of $0.0670 to $6.33, has elicited a strong bullish reaction from retail traders.<h2 class="st-heading-2">Insider Accumulates AiRWA Stock</h2>In an amended Schedule 13D filing with the SEC, AiRWA confirmed the stake build by director Michael Anthony Belfiore, which the company disclosed earlier this month. A Schedule 13D is filed by a person who acquires more than 5% of a voting class of a company’s stock, and who does not otherwise qualify to file a short-form report on Schedule 13G. It has to be filed within 10 days of the purchase of more than 5% stake.&nbsp;The company filed a Form 4 with the SEC on Oct. 15, stating that Belfiore purchased 3.21 million AiWA stock shares between Oct. 8 and Oct. 10, valued at $1.03 million. According to the 13D filing, Belfiore now holds a 22.1% stake in AiRWA.AiRWA, formerly Connexa Sports Technologies, rebranded itself to the present name on Oct. 7, underlining its thrust into the Web3 space and blockchain technology. In late August, the company, which was then called Connex Sports, struck a $500 million agreement with Singapore-based JuCoin to establish aiRWA, a next-generation digital asset platform jointly.&nbsp;According to the companies, the venture will focus on real-world asset (RWA) tokenization aimed at bringing traditional investments such as real estate, government bonds, and fine arts into a digital format. As part of the deal, JuCoin committed a $100 million investment in AiRWA, including about $30 million of Solana (SOL) tokens.<h2 class="st-heading-2">How Retail Feels About AiRWA Stock</h2>On Stocktwits, retail sentiment toward AiRWA stock shifted to ‘extremely bullish’ from the ‘bullish’ mood seen a day ago. The message volume remained at ‘extremely high’ levels. Retail chatter spiked nearly 3,500% in the 24 hours leading up to late Tuesday.<figure class="image"><img style="aspect-ratio:621/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_22_at_1_55_49_AM_png_5452a973dc.webp" alt="Screenshot 2025-10-22 at 1.55.49 AM.png" width="621" height="57"><figcaption>YYAI sentiment and message volume as of 1:55 a.m. ET, Oct. 22 | source: Stocktwits</figcaption></figure>One bullish user said “FOMO” fear will kick in once the stock reaches $0.50, and predicted a move to $1. Another user noted that retail traders’ support could push the price past the level.<stembedurl>https://stocktwits.com/ineedmore/message/633174405</stembedurl><stembedurl>https://stocktwits.com/ineedmore/message/633172951</stembedurl>AirWA stock, which fell 19.18% on Tuesday to $0.0809, was seen jumping 44% in overnight trading, according to Yahoo Finance.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-pega-stock-surge-over-13-in-after-hours-trading/cLGPxWaR3pl">Why Did PEGA Stock Surge Over 13% In After-Hours Trading?</a>

YYAI Stock Rockets After Insider Buying Reveal: Retail Trader FOMO Builds

In an amended regulatory filing, AiRWA confirmed a stake built by director Michael Anthony Belfiore.

Shares of Achieve Life Sciences, Inc. (ACHV) soared 32% on Friday afternoon after the company said that the U.S. Food and Drug Administration (FDA) awarded the company a Commissioner's National Priority Voucher (CNPV) for its Cytisinicline.The voucher is only available to nine programs in the program’s inaugural year. The program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.Achieve Life Sciences’ Cytisinicline is indicated for nicotine e-cigarette or vaping cessation. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168544/0/en/Achieve-Life-Sciences-Receives-FDA-Commissioner-s-National-Priority-Voucher-for-Cytisinicline-for-Treatment-of-Nicotine-Dependence-for-E-cigarette-or-Vaping-Cessation.html">said</a>.In a mid-stage trial, participants treated with Cytisinicline were found to be 2.6 times more likely to quit using nicotine e-cigarettes or vapes compared to placebo. The FDA has agreed on a late-stage trial design that, together with the mid-stage data, would support an application for approval in vaping cessation.In September, the FDA accepted the company’s application for Cytisinicline as a treatment for smoking cessation. The agency is expected to decide on the application by June 20, 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_1_41_17_PM_png_6eea8f50e0.webp" alt="ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>Other drugs awarded the voucher under the FDA program include Merck Group’s infertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy Teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and more.ACHV stock is up by 15% this year and down by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a 13 year old schoolboy holds single-use Vapes for Recycling in Kingston on Thames, England. (Photo by Peter Dazeley/Getty Images)

Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.

Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts.Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ with a price target of $7, down from $18. Meanwhile, William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to ‘Market Perform’ from ‘Outperform’ without a price target. Wells Fargo kept its ‘Equal Weight’ rating on the shares but slashed the price target to $5 from $7.Kezar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-announces-regulatory-update-zetomipzomib">announced</a> on Thursday that it has initiated a process to explore strategic alternatives focused on maximizing shareholder value after being unable to align with the U.S. Food and Drug Administration on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis (AIH). Autoimmune hepatitis is a rare, chronic disease that predominantly affects women and, if left untreated, can lead to cirrhosis, liver failure, and hepatocellular carcinoma.However, the FDA Division of Hepatology and Nutrition cancelled a Type C meeting that was previously scheduled with Kezar in the fourth quarter to discuss a proposed study in AIH, the company said.Earlier this year, Kezar reported positive safety and efficacy data from a clinical trial in patients with refractory or relapsed AIH. However, the regulator requested that Kezar conduct a stand-alone study to define the pharmacokinetics of Zetomipzomib in subjects with significant hepatic impairment before the initiation of another clinical trial in AIH.This study would delay future trials of Zetomipzomib in AIH by approximately two years, the company said, while adding that the requirements put forth by the FDA would also hinder patient enrollment and participation.“While we remain excited about the potential of Zetomipzomib to be the first approved agent in AIH, we lack the resources to extend the development timeline,” CEO Chris Kirk said.The company also said it would be implementing a restructuring plan, including layoffs and other cash conservation measures, as part of the strategic alternative evaluation.William Blair said on Friday that it is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.Wells, however, thinks there could be upside if they return cash to shareholders or in a reverse merger scenario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZR">KZR stock</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_12_46_33_PM_png_393ca210c9.webp" alt="KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that $6.50 to $7 would be a good range for the stock.<stembedurl>https://stocktwits.com/StockBoyAri/message/632736011</stembedurl>Another user expressed doubts over the rally.<stembedurl>https://stocktwits.com/CMCanalyst/message/632743196</stembedurl>KZR stock is down by 9% this year and by about 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A">Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Veritone (VERI) stock became the third-most trending ticker on Stocktwits, and its shares fell nearly 17% in early trading after the company announced an equity offering of approximately 12.87 million shares of common stock&nbsp;at a purchase price of $5.83 per share.Notably, despite the slide, the stock was still trading at $6.98 at the time of writing.&nbsp;The aggregate gross proceeds from the offering are expected to be about $75 million, before deducting offering expenses payable by the company.&nbsp;Veritone said that it intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for working capital and general corporate purposes. The company said this could also include capital expenditures, debt service, and repayment of indebtedness.Retail sentiment on Veritone remained unchanged in the ‘extremely bullish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Tuesday, the company announced that it has secured major contract wins to deploy its Veritone Data Refinery (VDR) product offering. The firm also reported preliminary third-quarter results and said it expects revenue of $28.5 million to $28.7 million, compared with the prior forecast of $28 million to $30 million.Veritone also said it is now estimating an adjusted loss of $5.5 million to $6 million, compared to its initial expectation of an adjusted loss of $6.5 million to $6 million.<a href="https://stocktwits.com/symbol/VERI">Shares of Veritone</a> have gained over 121% this year and have jumped 74.5% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/above-food-stock-becomes-top-trending-ticker-on-stocktwits/ch6pPOfR3nm">Above Food Stock Becomes Top Trending Ticker On Stocktwits, Draws Massive Retail Interest After Breaking Out Above $5-Mark In October</a>

Why Did Veritone Stock Fall 17% Today?

Veritone said the purchase price is $5.83 per share in a registered direct offering, and the aggregate gross proceeds from the offering are expected to be about $75 million, before deducting offering expenses payable by the company. 

Shares of autonomous-vehicle (AV) technology company Cyngn, Inc. (CYN)&nbsp;rose over 0.50% in early premarket trading on Wednesday, suggesting they could witness follow-on buying after two consecutive sessions of gains.The strong rally in<a href="https://stocktwits.com/symbol/CYN">&nbsp;Cyngn stock</a> on Tuesday came after the company announced a<a href="https://stocktwits.com/news-articles/markets/equity/why-is-cyngn-stock-surging-22-percent-pre-market-today/ch6mo2wR3mL">&nbsp;commercial DriveMod Tugger deployment</a> with PepsiCo's (PEP) largest independent bottler in the U.S., G&amp;J Pepsi.&nbsp; DriveMod is Cyngn's autonomous vehicle technology that transforms industrial vehicles, such as forklifts and tuggers, into self-driving robots.Following the news, retail trader buzz&nbsp;surged, overwhelming the Cyngn stream on Stocktwits with messages. The message volume change on the Cyngn stream spiked 11,500% over the 24 hours leading up to late Tuesday. On Stocktwits, retail sentiment improved to 'extremely bullish' (87/100) as of early Wednesday, from 'bullish' the day before.<figure class="image"><img style="aspect-ratio:621/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_4_36_40_AM_png_0bbfe8acb5.webp" alt="Screenshot 2025-10-15 at 4.36.40 AM.png" width="621" height="53"><figcaption>CYN sentiment and message volume as of 4:35 a.m. ET, Oct. 15 | source: Stocktwits</figcaption></figure>A bullish user noted that the partnerships with Pepsi and Nvidia will provide Cyngn with cash for the next two years. In June, the company said its autonomous industrial vehicles, built on Nvidia&nbsp; Isaac and powered by DriveMod software, were currently operating in commercial environments to reduce labor costs, increase throughput, and improve safety.<stembedurl>https://stocktwits.com/kitir92/message/632357308</stembedurl>Another user expected the stock to trade above $10 on Wednesday.<stembedurl>https://stocktwits.com/time4themoon/message/632349740</stembedurl>Cyngn stock is down about 96% year-to-date, grossly underperforming the broader market. According to Koyfin, the average price target for the stock is $12, suggesting roughly 110% upside from current levels. Cyngn stock has traded in a 52-week range of $3.62-$1,312.50.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/asml-stock-rises-premarket-after-q3-results/ch6nYiSR3Zy">ASML Stock Rises Premarket After Q3 Results: Margin Outlook Raised On AI Chip Boom</a>

 In this photo illustration, the Cyngn logo is seen displayed on a smartphone screen.

Cyngn Stock Eyes Third Day Of Gains: What's Driving The Buzz?

Cyngn stock is down about 96% year-to-date, grossly underperforming the broader market.

Shares of Veritone, Inc. (VERI), a provider of artificial intelligence (AI) computing solutions, rallied about 54% in Tuesday’s premarket session, after the company announced new contracts and also preannounced potential third-quarter revenue shortfall.If the after-hours jump carries over into Wednesday’s session,&nbsp;<a href="https://stocktwits.com/symbol/VERI">Veritone stock</a>&nbsp;will be on track to record its best day ever. On Stocktwits, retail sentiment toward the stock flipped to ‘extremely bullish’ (76/100) as of late Tuesday from ‘bearish’ the day before. The message volume spiked to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:621/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_10_48_21_PM_png_94b26160eb.webp" alt="Screenshot 2025-10-14 at 10.48.21 PM.png" width="621" height="56"><figcaption>VERI sentiment and message volume as of 10:45 p.m. ET, Oct. 14 | source: Stocktwits</figcaption></figure>The Irvine, California-based company said it has secured major contract wins to deploy its Veritone Data Refinery (VDR) product offering with leading hyperscalers. Data refining is the process of making data more accurate, consistent and useful for analysis and decision making.&nbsp;In a statement, the company said, “These partnerships underscore Veritone’s accelerated momentum in enabling the largest enterprises and model developers to transform proprietary, unstructured data into actionable, license-ready intelligence that fuels cognitive and generative AI development.”With the recent VDR contracts, the company’s near-term VDR pipeline and recent bookings totaled $40 million, a 100% increase from August. The contracts include those from both commercial and public-sector customers.CEO Ryan Steelberg said, “We’re proud to see the industry increasingly recognize Veritone as a trusted partner for the unstructured training data ecosystem, and we are firmly on track to have formalized partnerships with nearly every major hyperscaler by the end of 2025.”The company also announced preliminary third-quarter results, expecting an adjusted loss of $5.5 million to $6 million,&nbsp;lower than the guidance for an adjusted loss of $6.5 million to $6 million it issued in early August. The company expects revenue of $28.5 million to $28.7 million versus the previous guidance of $28 million to $30 million. Analysts, on average, expect the topline to come in at $28.7, according to Fiscal.ai.Veritone stock was among the top five trending equity tickers on Stocktwits as of late Tuesday.A bullish user said the fair price for the stock after the contract wins is $30. It ended Tuesday’s session up 4.40% at $5.46.<stembedurl>https://stocktwits.com/Alalamy/message/632348164</stembedurl>Another user pointed to a stock price target hike and urged fellow retail traders to “hold for the long term.”<stembedurl>https://stocktwits.com/Daebak64/message/632347524</stembedurl>The stock has climbed about 67% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-plans-to-make-smart-home-devices-in-vietnam-report/ch6niNER3Z9">Apple Plans To Make Smart Home Devices In Vietnam, Breaking Tradition Of China-First Manufacturing: Report</a>

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Why Veritone Stock Skyrocketed In After-Hours Trading Today

With the recent VDR contracts, the company’s near-term VDR pipeline and recent bookings totaled $40 million, a 100% increase from August.

Shares of Emerson Radio, one of the oldest consumer electronics manufacturers in the U.S., rose 20% in after-market trading on Wednesday after a sharp rally in recent sessions, piquing the interest of retail investors.The&nbsp;<a href="https://stocktwits.com/symbol/MSN">MSN stock</a> rose 65% in the previous two sessions to&nbsp;close at&nbsp;its highest level in over three years, without an apparent catalyst. The company is listed on the NYSE American, a platform for trading shares of small- and micro-cap companies operated by NYSE, and had a market cap of $15.7 million as of Wednesday.<figure class="image"><img style="aspect-ratio:614/71;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_11_44_09_AM_png_14d0034d6d.webp" alt="Screenshot 2025-10-09 at 11.44.09 AM.png" width="614" height="71"><figcaption>MSN sentiment and message volume as of October 9 | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for the stock shifted to nearly the highest possible level, 'extremely bullish' (98/100) as of early Thursday, up from 'neutral' two days prior.&nbsp;Over the past 24 hours, the message volume for the ticker increased by 278%, while the number of watchers on Stocktwits jumped by 18%.Several users reported buying shares, adding the stock to their watchlists, and forecasting a price level of $2 or more in the coming days."$MSN Anything below $1 is a buy here," said one user.<stembedurl>https://stocktwits.com/InterstellerRides/message/631603439</stembedurl>New Jersey-based Emerson Radio produces and sells a range of home appliances, including microwave ovens, refrigerators, fans, clock radios, Bluetooth speakers, and televisions.Year-to-date, the company's shares have gained 77.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on October 04, 2023 in New York City. 

Micro-Cap Emerson Radio Stock Surges By Two-Thirds In 2 Days, And Then Some More, Piquing Retail Traders

The home appliance company's shares snagged nearly the highest possible sentiment reading on Stocktwits.

Special purpose acquisition company (SPAC) Churchill Capital Corp X (CCCX)&nbsp;shares were up over 4% in early premarket trading on Wednesday, poised to extend their winning streak to six sessions. The optimism over the shell company’s impending merger with the privately held quantum computing company Infleqtion has increased retail traders’ interest in Churchill Capital stock.The stock jumped 14% on Tuesday after Andrew Left’s Citron Research said the company is undervalued. Comparing Infleqtion with Rigetti (RGTI), the firm stated that the former actually sells quantum hardware, sensors, and atomic clocks, whereas the latter remains an underfunded science project.If both companies shared the same market capitalization, Churchill Capital should be trading at over $60, Citron said. Notwithstanding the stock's 80% rally seen since Sept. 8, when it announced its plan to merge with Infleqtion, it still traded at $18.23.Citron said, “Most investors don’t realize Infleqtion already has real defense and aerospace contracts — with DARPA and the Air Force Research Lab — and is shipping deployable quantum systems today. Rigetti isn’t close to that.” The firm recommended that investors should own three Churchill Corp shares for every single Rigetti stock they own.In the press statement announcing the SPAC deal, Churchill Capital stated in early September that Infleqtion has real-world deployments in computing and precision sensing and is poised to accelerate its scale. It touted that Infleqtion’s clientele included&nbsp; Nvidia, the U.S. Department of Defense and NASA, among others.To date, Infleqtion has sold three quantum computers and hundreds of quantum sensors, generating approximately $29 million in trailing twelve-month revenue as of June 30, 2025. The company expects roughly $50 million of booked and awarded business at year-end 2025, and has identified a potential customer pipeline exceeding $300 million.On Stocktwits, retail sentiment toward Churchill Capital stock improved further into the ‘extremely bullish’ territory by early Wednesday, and the message volume on the stream also remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/55;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_08_at_4_24_48_AM_png_7c7969a459.webp" alt="Screenshot 2025-10-08 at 4.24.48 AM.png" width="626" height="55"><figcaption>CCCX sentiment and message volume as of 4:20 a.m. ET, Oct. 8 | source: Stocktwits</figcaption></figure>A bullish user expected the stock to open at $ 20 or higher amid the ongoing momentum.<stembedurl>https://stocktwits.com/moonstocks777/message/631429325</stembedurl>Another user, who identified themselves as one on the bullish camp, wondered whether it was too late to get into the stock and also whether it is a good long-term hold.<stembedurl>https://stocktwits.com/shercat06/message/631422369</stembedurl>Quantum computing stocks have been on a tear this year, having picked up from where they left off in late 2024, as investors are sold on the promise held by these companies.&nbsp; The&nbsp;<a href="https://stocktwits.com/symbol/QTUM">Defiance Quantum ETF (QTUM)</a> has gained nearly 38% year-to-date, outperforming the broader market and the tech sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-confluent-stock-is-soaring-over-19-in-today-s-premarket/ch6EfX6R3LN">Why Confluent Stock Is Soaring Over 19% In Today’s Premarket</a>

Quantum Computing, Quantum Physics, Quantum mechanics, Science, Technology. (Representative image courtesy of Just_Super via Getty Images)

Why SPAC Churchill Capital’s Stock Is Jumping Premarket Today

Citron recommended that investors should own three Churchill Corp shares for every single Rigetti stock they own.

BlackRock Institutional Trust Company N.A. - iShares Micro-Cap ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$156.58
Prev Close	$155.60
Open	$155.64
Dividend Yield	N/A
50-Day Moving Average	$149.21
Beta	N/A
Avg. Volume	40,872.67
PE Ratio	N/A

52-Week High	$161.95
52-Week Low	$95.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF